论文部分内容阅读
目的研究Cyclin D1基因(A870G)多态性与中国女性乳腺癌临床病理特征的关系,探讨其在乳腺癌预后中的潜在意义。方法本研究运用PCR-RFLP方法对433例原发性乳腺癌患者外周血进行Cyclin D1基因(A870G)多态性检测,了解其频率分布,用Pearsonχ2检验分析基因型与乳腺癌临床病理特征的关系。结果①Cyclin D1基因(A870G)多态与乳腺癌患者的年龄、月经状态、肿瘤大小、腋窝淋巴结转移、TNM分期、ER状态和erbB2蛋白表达无统计学意义(P>0.05)。②携带GG基因型的患者与AA和AG基因型患者的ER、PR状态比较有统计学意义(P=0.026;P=0.004))。携带GG基因型的患者的ER阳性率77.4%(72/93);AA+AG基因型患者的ER阳性率65.3%(222/340);GG基因型患者PR阳性率73.1%(68/93),AA+AG基因型患者PR阳性率56.8%(193/340)。结论 Cyclin D1基因(A870G)多态与乳腺癌患者的ER、PR状态相关,提示这种多态性可能与乳腺癌患者的内分泌治疗及预后有关,初步结论尚需有随访资料的大样本进一步验证。
Objective To investigate the relationship between the Cyclin D1 gene (A870G) polymorphism and the clinicopathological features of breast cancer in Chinese women, and to explore its potential significance in the prognosis of breast cancer. Methods The PCR-RFLP method was used to detect the polymorphism of Cyclin D1 gene (A870G) in 433 cases of primary breast cancer patients and its frequency distribution was analyzed. Pearsonχ2 test was used to analyze the relationship between the genotypes and clinicopathological features of breast cancer . Results ① The age, menstrual status, tumor size, axillary lymph node metastasis, TNM stage, ER status and erbB2 protein expression were not significantly different between Cyclone D1 gene (A870G) polymorphism and breast cancer patients (P> 0.05). ② The status of ER and PR in patients with GG genotypes and AA and AG genotypes was statistically significant (P = 0.026; P = 0.004). The positive rate of ER in patients with GG genotype was 77.4% (72/93). The positive rate of ER in patients with AA + AG genotype was 65.3% (222/340). The positive rate of PR in patients with GG genotype was 73.1% (68/93) The positive rate of PR in patients with AA + AG genotype was 56.8% (193/340). Conclusion The polymorphism of Cyclin D1 gene (A870G) is correlated with ER and PR status in patients with breast cancer, suggesting that this polymorphism may be related to the endocrine therapy and prognosis of patients with breast cancer. The preliminary conclusion still needs to be verified by large sample of follow-up data .